Article
Impact of initial treatment and prognostic factors on postprogression survival in BRAF-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis of four clinical trials.
Journal of translational medicine - 3 Aug 2020
Ascierto Paolo A, Ribas Antoni, Larkin James, McArthur Grant A, Lewis Karl D, Hauschild Axel, Flaherty Keith T, McKenna Edward, Zhu Qian, Mun Yong, Dréno Brigitte
Abstract excerpt
BACKGROUND: We sought to identify patient subgroups with distinct postprogression overall survival (ppOS) outcomes and investigate the impact of original treatment assignment and initial postprogression treatment (ppRx) on ppOS. METHODS: Recursive partitioning analysis (RPA) was performed to model relationships between prespecified covariates and ppOS in patients with BRAFV600-mutated metastatic melanoma who had...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.